These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1245 related articles for article (PubMed ID: 33956791)

  • 1. Modelling optimal vaccination strategy for SARS-CoV-2 in the UK.
    Moore S; Hill EM; Dyson L; Tildesley MJ; Keeling MJ
    PLoS Comput Biol; 2021 May; 17(5):e1008849. PubMed ID: 33956791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
    Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
    Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
    McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC
    Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are COVID vaccination programmes working? Scientists seek first clues.
    Mallapaty S
    Nature; 2021 Jan; 589(7843):504-505. PubMed ID: 33483685
    [No Abstract]   [Full Text] [Related]  

  • 5. Lockdowns and the COVID-19 pandemic: What is the endgame?
    Lytras T; Tsiodras S
    Scand J Public Health; 2021 Feb; 49(1):37-40. PubMed ID: 32981448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in attitudes to vaccination as a result of the COVID-19 pandemic: A longitudinal study of older adults in the UK.
    Gallant AJ; Nicholls LAB; Rasmussen S; Cogan N; Young D; Williams L
    PLoS One; 2021; 16(12):e0261844. PubMed ID: 34941951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why scientists worldwide are watching UK COVID infections.
    Taylor L
    Nature; 2021 Nov; 599(7884):189-190. PubMed ID: 34732879
    [No Abstract]   [Full Text] [Related]  

  • 9. Epidemic control by social distancing and vaccination: Optimal strategies and remarks on the COVID-19 Italian response policy.
    d'Onofrio A; Iannelli M; Manfredi P; Marinoschi G
    Math Biosci Eng; 2024 Jul; 21(7):6493-6520. PubMed ID: 39176405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of vaccination on the COVID-19 pandemic in U.S. states.
    Chen X; Huang H; Ju J; Sun R; Zhang J
    Sci Rep; 2022 Jan; 12(1):1554. PubMed ID: 35091640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long road.
    Cohen J
    Science; 2021 Feb; 371(6531):768-772. PubMed ID: 33602838
    [No Abstract]   [Full Text] [Related]  

  • 12. Trajectory of individual immunity and vaccination required for SARS-CoV-2 community immunity: a conceptual investigation.
    Saad-Roy CM; Levin SA; Metcalf CJE; Grenfell BT
    J R Soc Interface; 2021 Feb; 18(175):20200683. PubMed ID: 33530857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal control strategies on COVID-19 infection to bolster the efficacy of vaccination in India.
    Rajput A; Sajid M; Tanvi ; Shekhar C; Aggarwal R
    Sci Rep; 2021 Oct; 11(1):20124. PubMed ID: 34635703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study.
    Jentsch PC; Anand M; Bauch CT
    Lancet Infect Dis; 2021 Aug; 21(8):1097-1106. PubMed ID: 33811817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the impact of vaccination strategies on the spread of COVID-19, including a novel household-targeted vaccination strategy.
    Voigt A; Omholt S; Almaas E
    PLoS One; 2022; 17(2):e0263155. PubMed ID: 35108311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity.
    Blasi F; Gramegna A; Sotgiu G; Saderi L; Voza A; Aliberti S; Amati F
    Respir Med; 2021; 180():106355. PubMed ID: 33721697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of vaccination by priority group on UK deaths, hospital admissions and intensive care admissions from COVID-19.
    Cook TM; Roberts JV
    Anaesthesia; 2021 May; 76(5):608-616. PubMed ID: 33572007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could COVID-19 be contained in poor populations by herd immunity rather than by strategies designed for affluent societies or potential vaccine(s)?
    Ruppel A; Halim MI; Kikon R; Mohamed NS; Saebipour MR
    Glob Health Action; 2021 Jan; 14(1):1863129. PubMed ID: 33397199
    [No Abstract]   [Full Text] [Related]  

  • 19. Population Immunity Against COVID-19 in the United States.
    Moghadas SM; Sah P; Shoukat A; Meyers LA; Galvani AP
    Ann Intern Med; 2021 Nov; 174(11):1586-1591. PubMed ID: 34516275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five reasons why COVID herd immunity is probably impossible.
    Aschwanden C
    Nature; 2021 Mar; 591(7851):520-522. PubMed ID: 33737753
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 63.